Advertisement For over a decade, the antitrust enforcers at the Federal Trade Commission have challenged the type of patent settlement where a brand-name drug manufacturer pays a prospective generic manufacturer to settle patent challenges, and the generic manufacturer agrees not to bring its generic to market for a specified number of years. The lower federal … Continue reading Supreme Court Holds That Reverse Payment Patent Settlements Are Subject to Antitrust Scrutiny